Search
for
Sort by
Research 61–90 of 532
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- The Sebaceous Gland - Friend or Foe?
- <i>In‐silico</i> Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its <i>In‐vitro</i> Evaluation
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Cedrol in ginger (Zingiber officinale) as a promising hair growth drug: The effects of oral and external administration on hair regeneration and its mechanism
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- LB1048 Effectiveness of OR-101 in a murine model of atopic dermatitis
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- Advances in the mechanism and new therapies of alopecia areata
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study